Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 10/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733956 | 0.83 | CYP11B1 (0.35) | CYP11B1CYP11B2EPAS1KIF11NOTUM | |
| SCHEMBL19585261 | 0.79 | KIF11 (0.36) | CYP11B1CYP11B2KIF11MPLHSD11B1 | |
| SCHEMBL27831995 | 0.77 | HTT (0.36) | KIF11NOTUMLMNAHTTSMN1; SMN2 | |
| SCHEMBL17806030 | 0.76 | ACHE (0.33) | — | |
| SCHEMBL13199169 | 0.75 | AR (0.38) | CYP11B1CYP11B2KIF11NOTUMHSD11B1 | |
| SCHEMBL27334609 | 0.74 | AR (0.39) | CYP11B1CYP11B2EPAS1KIF11MPL | |
| SCHEMBL5733897 | 0.74 | NOTUM (0.36) | CYP11B1CYP11B2NOTUMHSD11B1LMNA | |
| SCHEMBL13990215 | 0.73 | KIF11 (0.38) | CYP11B1CYP11B2KIF11MPLHSD11B1 | |
| SCHEMBL6705688 | 0.73 | CYP11B1 (0.37) | CYP11B1CYP11B2EPAS1KIF11NOTUM | |
| SCHEMBL2878061 | 0.73 | NOTUM (0.38) | CYP11B1CYP11B2NOTUMHSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | CYP11B1 657/4885CYP11B2 492/4885EPAS1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.